News & Events

Finances

Xeltis lands €15 million European financing from EIB

The European Investment Bank (EIB) has signed a €15 million quasi-equity financing agreement with Xeltis. The EIB’s non-dilutive financing will…

Content TeamNovember 22, 2021

Publications

ETR Insights from Xeltis restorative pulmonary valve in Acta Biomaterialia

The latest insights on the fascinating mechanisms behind endogenous tissue restoration (ETR), the process that transforms Xeltis devices into living…

adminOctober 14, 2021

Publications

Superior biocompatibility of Xeltis materials vs conventional heart valve devices published in JBMR

Xeltis’ polymers have shown superior pro-healing response and no calcification compared to conventional biological heart valve devices in preclinical trial…

adminAugust 6, 2021

Publications

Excellent performance and safety data on Xeltis bio-restorative technology published

Promising early outcomes from two clinical trials of Xeltis pulmonary valve confirm the excellent safety and performance of its bio-restorative…

adminMarch 12, 2021

Events

Xeltis living heart valves to epitomize innovative medtech at the Spirit of Bern

Xeltis has been selected with three other Swiss companies to illustrate how medtech innovation can pave new ways to improve…

adminFebruary 25, 2021

Finances

Xeltis’ closes €10.5 million Series D financing

Xeltis closed a €10.5 million Series D financing round to support its vascular and valve trial programs this week. The…

adminSeptember 5, 2019

Publications

Xeltis’ RestoreX™ in Cardiovascular Pathology

Peer-reviewed journal Cardiovascular Pathology published positive one-year in-vivo data on Xeltis’ RestoreX™ technology platform in its latest issue. According to…

adminMarch 8, 2019

Clinical Trials

XABG preclinical trial showed superior performance vs harvested veins at one year

Results from preclinical trials of Xeltis restorative coronary artery bypass graft XABG showed superior performance of the Xeltis graft compared…

Content TeamMarch 11, 2022

Cookie	Duration	Description
cookielawinfo-checkbox-analytics	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Analytics".
cookielawinfo-checkbox-functional	11 months	The cookie is set by GDPR cookie consent to record the user consent for the cookies in the category "Functional".
cookielawinfo-checkbox-necessary	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookies is used to store the user consent for the cookies in the category "Necessary".
cookielawinfo-checkbox-others	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Other.
cookielawinfo-checkbox-performance	11 months	This cookie is set by GDPR Cookie Consent plugin. The cookie is used to store the user consent for the cookies in the category "Performance".
CookieLawInfoConsent	1 year	CookieYes sets this cookie to record the default button state of the corresponding category and the status of CCPA. It works only in coordination with the primary cookie.
viewed_cookie_policy	11 months	The cookie is set by the GDPR Cookie Consent plugin and is used to store whether or not user has consented to the use of cookies. It does not store any personal data.

Cookie	Duration	Description
_ga	1 year 1 month 4 days	Google Analytics sets this cookie to calculate visitor, session and campaign data and track site usage for the site's analytics report. The cookie stores information anonymously and assigns a randomly generated number to recognise unique visitors.
_ga_*	1 year 1 month 4 days	Google Analytics sets this cookie to store and count page views.

Keep up to date with all of our latest news and events

LATEST NEWS

Xeltis successfully passes evaluation phase for €10million investment from European Innovation Council

Xeltis lands €15 million European financing from EIB

ETR Insights from Xeltis restorative pulmonary valve in Acta Biomaterialia

Superior biocompatibility of Xeltis materials vs conventional heart valve devices published in JBMR

Excellent performance and safety data on Xeltis bio-restorative technology published

Xeltis living heart valves to epitomize innovative medtech at the Spirit of Bern

Xeltis’ closes €10.5 million Series D financing

Xeltis’ RestoreX™ in Cardiovascular Pathology

XABG preclinical trial showed superior performance vs harvested veins at one year

Press Releases

Xeltis starts pivotal clinical trial with first ever restorative synthetic hemodialysis access graft

Xeltis presents promising FIH data on restorative hemodialysis access graft at ESVS congress

Xeltis receives commitment from Grand Pharma to invest €15M

Xeltis lands €15 million European financing from EIB

Xeltis initiates first-ever pivotal trial of a synthetic restorative pulmonary heart valve

Media

ETR Powered Platform

Pulmonary Heart Valve

Prof. Mauro Gargiulo

Professor Thierry Carrel

Martijn Cox

Professor Jean-Marie Lehn

A Patient’s Perspective

Global Impact of Heart Valve Disease